65 research outputs found
Recommended from our members
IgG4 Immunostaining and Its Implications in Orbital Inflammatory Disease
Objective
IgG4-related disease is an emerging clinical entity which frequently involves tissue within the orbit. In order to appreciate the implications of IgG4 immunostaining, we analyzed gene expression and the prevalence of IgG4- immunostaining among subjects with orbital inflammatory diseases.
Methods
We organized an international consortium to collect orbital biopsies from 108 subjects including 22 with no known orbital disease, 42 with nonspecific orbital inflammatory disease (NSOI), 26 with thyroid eye disease (TED), 12 with sarcoidosis, and 6 with granulomatosis with polyangiitis (GPA). Lacrimal gland and orbital adipose tissue biopsies were immunostained for IgG4 or IgG secreting plasma cells. RNA transcripts were quantified by Affymetrix arrays.
Results
None of the healthy controls or subjects with TED had substantial IgG4 staining. Among the 63 others, the prevalence of significant IgG4-immunostaining ranged from 11 to 39% depending on the definition for significant. IgG4 staining was detectable in the majority of tissues from subjects with GPA and less commonly in tissue from subjects with sarcoidosis or NSOI. The detection of IgG4+ cells correlated with inflammation in the lacrimal gland based on histology. IgG4 staining tissue expressed an increase in transcripts associated with inflammation, especially B cell-related genes. Functional annotation analysis confirmed this.
Conclusion
IgG4+ plasma cells are common in orbital tissue from patients with sarcoidosis, GPA, or NSOI. Even using the low threshold of 10 IgG4+ cells/high powered field, IgG4 staining correlates with increased inflammation in the lacrimal gland based on histology and gene expression
The Metallicity-Luminosity Relation, Effective Yields, and Metal Loss in Spiral and Irregular Galaxies
I present results on the correlation between galaxy mass, luminosity, and
metallicity for a sample of spiral and irregular galaxies having well-measured
abundance profiles, distances, and rotation speeds. Additional data for low
surface brightness galaxies from the literature are also included for
comparison. These data are combined to study the metallicity-luminosity and
metallicity-rotation speed correlations for spiral and irregular galaxies. The
metallicity luminosity correlation shows its familiar form for these galaxies,
a roughly uniform change in the average present-day O/H abundance of about a
factor 100 over 11 magnitudes in B luminosity. However, the O/H - V(rot)
relation shows a change in slope at a rotation speed of about 125 km/sec. At
faster V(rot), there appears to be no relation between average metallicity and
rotation speed. At lower V(rot), the metallicity correlates with rotation
speed. This change in behavior could be the result of increasing loss of metals
from the smaller galaxies in supernova-driven winds. This idea is tested by
looking at the variation in effective yield, derived from observed abundances
and gas fractions assuming closed box chemical evolution. The effective yields
derived for spiral and irregular galaxies increase by a factor of 10-20 from
V(rot) approximately 5 km/sec to V(rot) approximately 300 km/sec, asympotically
increasing to approximately constant y(eff) for V(rot) > 150 km/sec. The trend
suggests that galaxies with V(rot) < 100-150 km/sec may lose a large fraction
of their SN ejecta, while galaxies above this value tend to retain metals.Comment: 40 pages total, including 7 encapsulated postscript figures. Accepted
for publication in 20 Dec 2002 Ap
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome
Assumption without representation: the unacknowledged abstraction from communities and social goods
We have not clearly acknowledged the abstraction from unpriceable “social goods” (derived from
communities) which, different from private and public goods, simply disappear if it is attempted to
market them. Separability from markets and economics has not been argued, much less established.
Acknowledging communities would reinforce rather than undermine them, and thus facilitate
the production of social goods. But it would also help economics by facilitating our understanding
of – and response to – financial crises as well as environmental destruction and many social problems,
and by reducing the alienation from economics often felt by students and the public
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome
Hypocomplementemic interstitial nephritis with long-term follow-up
Prednisone-sensitive hypocomplementemia, renal insufficiency, and kidney biopsy demonstrating severe tubulointerstitial nephritis (TIN), storiform fibrosis, and tubulointerstitial immune deposits are typical of IgG4-related tubulointerstitial nephritis and hypocomplementemic interstitial nephritis. A diagnosis of hypocomplementemic interstitial nephritis requires clinical and pathologic exclusion of IgG4-related tubulointerstitial nephritis. We describe a patient with hypocomplementemic interstitial nephritis who did not develop diagnostic features of IgG4 related disease (RD) over 2-year follow-up. We conclude that hypocomplementemic interstitial nephritis could be on a biologic spectrum with IgG4-related disease, but not all cases will develop the abundance of IgG4-positive plasma cells, systemic manifestations, or elevated immunoglobulin levels characteristic of IgG4-RD
Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506
Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Acute cyclosporine (CsA) nephrotoxicity is characterized by a reduction of glomerular filtration rate (GFR), hypomagnesemia and tubular injury. The mechanisms of CsA's immunosuppressive action and presumably its nephrotoxicity are mediated through inhibition of the renal phosphatase, calcineurin. FK506 (FK), which has a different chemical structure and binding immunophilin, also inhibits calcineurin. We compared the renal effects of these drugs to those of rapamycin (RAPA), which although similar in structure and intracellular binding to FK, does not work by changing calcineurin activity. Rats were given CsA (15 mg/kg/s.c), FK (6 mg/kg/p.o.), RAPA (3 mg/kg/p.o.) or vehicle (V) for two weeks on a low salt diet. CsA and FK strikingly decreased urinary excretion of nitric oxide, renal blood flow and GFR, whereas RAPA did not. In contrast, all these three drugs caused significant hypomagnesemia associated with inappropriately high fractional excretion of magnesium, suggesting renal magnesium wasting. In addition, with all three drugs there were lesions in the rat kidneys consisting of tubular collapse, vacuolization and nephrocalcinosis. We thus showed that only the calcineurin inhibitors produced glomerular dysfunction in an acute experimental model of nephrotoxicity. The mechanism of hypomagnesemia and tubular injury induced by all three immunosuppressive drugs is unclear but may be independent of calcineurin. The mechanism of renal vasoconstriction on the other hand may be related to inhibition of calcineurin
Buyer beware? : does the information provided with herbal products available over the counter enable safe use?
Background: Herbal products obtained over the counter are commonly used in Europe, North America and Australia.
Although there is concern about a lack of information provided to consumers to allow the safe use of these products,
there has been no published research to confirm these fears. In this study, we evaluated written information provided
with commonly used herbal products in the UK in advance of a European Union Directive issued in April 2011 that
tightened regulations for some herbal products, including requirements to provide safety information.
Methods: Five commonly used herbal products were purchased from pharmacies, health food shops and
supermarkets: St John’s wort, Asian ginseng, echinacea, garlic and ginkgo. Written information provided with the
products (on the package or on a leaflet contained in the package) was evaluated for inclusion of each of the key
safety messages included in the monographs of the US National Center for Complementary and Alternative
Medicine. Specifically, we looked for information on precautions (such as Asian ginseng not being suitable for
people with diabetes), interactions with conventional medicines (such as St John’s wort with the contraceptive pill
and warfarin) and side effects (such as ginkgo and allergic reactions).
Results: Our analysis showed that, overall, 51 (75%) of 68 products contained none of the key safety messages.
This included 4 of 12 St John’s wort products, 12 of 12 ginkgo products, 6 of 7 Asian ginseng products, 20 of 21
garlic products and 9 of 13 echinacea products. The two products purchased that are registered under the new
European Union regulations (for St John’s wort) contained at least 85% of the safety messages.
Conclusions: Most of the herbal medicine products studied did not provide key safety information which
consumers need for their safe use. The new European Union legislation should ensure that St John’s wort and
echinacea products will include the previously missing information in due course. The legislation does not apply to
existing stock. Depending on therapeutic claims made by manufacturers, garlic, ginkgo and Asian ginseng products
may not be covered by the legislation and can continue to be bought without the safety information. Also,
consumers will still be able to buy products over the internet from locations outside European Union jurisdiction.
Potential purchasers need to know, in both the short term and the long term, how to purchase herbal products
which provide the information they need for the safe use of these products
Experimental Gentamicin Nephrotoxicity: Effect of Streptozotocin-Induced Diabetes'
ABSTRACT Methods Three-month-old Fischer 344 rats were obtained from Simonsen Laboratories (Gilroy, CA). All animals were provided standard rat chow ABBREVIATIONS: CCR, creatinine clearance; SCR, serum creatinine; GFR, glomerular filtration rate; CN, inulin clearance; PAH, p-aminohippurate
- …